On August 20, 2018, Benny, CEO of B. Medical, visited WAT Med. Both parties held an in-depth discussion of the cooperation details concerning the strategic layout of Israeli market and the brand building.
Benny and WAT Med knew each other on Medica 2017, an expo held in Germany. Benny said he was attracted by “migraine”. At the sight of this product, he believed that it would have a huge market. “In Israel, more than one third of people suffer from migraine”. “Every year, about 32 billion dollars are spent on the headache-curing drugs”. Designed to provide an affordable and low-cost device to cure migraine to reduce the drug use, the HeadaTerm has greatly reduced the therapy cost and side effect. Benny started to investigate and survey the Israeli market once the expo ended. Meanwhile, he and WAT Med drilled down into the issues about market promotion and channel building for HeadaTerm and EmeTerm.
During the meeting, the parties had a very agreeable talk. According to Benny, the registration of these two products proceeds very smoothly in Israeli Health Ministry. It is expected that HeadaTerm and EmeTerm will officially enter the Israeli market in about one month after the registration process ends. In addition, HMO is the largest medical insurance organization in Israel. Any Israeli citizen who wants to buy medical products must become a member of HMO. Now, Benny has established cooperation relationship with Israel’s HMO, so it would be very soon for HeadaTerm and EmeTerm to enter into the HMO channel.
WAT Med welcomes partner from around the world for visiting, cooperation and exchange. For both WAT Med and Benny, August 20 was a meaningful day. “This is the happiest and most unforgettable day I have ever had”, said Benny. WAT Med devotes itself to providing innovative products and services for the field of global and individual medical devices, as well as competitive medical products for its partners worldwide, thus to achieve win-win development.
